prr target 60 - 62 cents but when

PRR target 60 - 62 cents but when

Have a read below
http://www.thetradercentral.com/2011/04/prima-biomed/

Prima Biomed

With the increasing interest in biotech companies after substantial rises in companies such as Mesoblast, ASX listed stocks that are developing and trialling new biological- technology are becoming increasingly attractive to investors and institutions. Today we will look at one of the more high potential biotech stocks; Prima Biomed.

Prima Biomed is an Australian biotech specialising in cancer treatment. The company focuses on developing anti-cancer therapeutics based on the emerging technology of immunotherapy. The new technology involves stimulating the patient�s immune system to attack the malignant tumour cells that are responsible for the disease. Stimulation of the patient�s immune system can be achieved by two different methods; injecting a cancer vaccine which trains the immune system to recognise tumour cells and eliminate them from the body. The second method involves the administration of therapeutic antibodies, which recruits the immune system to destroy the tumour cells.

Products and Technologies

Cvac immunothearpy has been designed as a treatment for Ovarian Cancer. The Cancer is an ever increasing concern for Australian women, According to the Ovarian Cancer council More than 1200 women are diagnosed with ovarian cancer in Australia each year and 800 women will die from the disease. Current treatment for Ovarian Cancer includes surgery, chemotherapy and radio therapy, these treatments are both expensive and can have significant side-effects for patients. Cvac offers patients a friendly alternative to these treatments which could potentially change the way the cancer is treated in the future. US based biotech Dendreon have already had great success with a their own cellular immunotherapy treatment ; Provenge. Dendreon�s success is a breakthrough in immunotherapy technology and provides some validation for Prima and their aspirations for Cvac

Cvac has completed Phase IIa clinical trials and focuses on the development of an ex-vivo immunotherapy for ovarian cancer. Currently Prima is undertaking a Phase IIb clinical study in the US and Australia, and has plans to commence in 2011.

Oppotunity and Valuation

Prima have a strong management team with an abundance of experience in biotechnology. With Cvac, Prima are well positioned to gain access into the estimated 3.2 billion dollar American market. If the technology proves to be successful with ovarian cancer there is a considerable chance that immunotherapy will be effective in treating other types of cancer. Very few Biotech�s have undertaken their own investigations into immunotherapies, if Cvac is succsesful there is every chance Prima may become a target for a takeover. Cvac is just one of the treatments being undertaken by Prima, the company is also researching Oral HPV vaccine and Humanized monocolnal antibody.

Broker Valuations

National Securities: 62c target
Southern Cross Equities: 60c target